Immune Design Corp(NASDAQ:IMDZ) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $1.13M. Analysts estimated a revenue of $1.85M. Earnings per share were $-0.71. Analysts had estimated an EPS of $-0.68.
Immune Design Corp (IMDZ) shares turned negative on Wednesdays trading session with the shares closing down -0.17 points or -2.38% at a volume of 37,532. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $7.18. The peak price level was also seen at $7.18 while the days lowest was $6.94. Finally the shares closed at $6.97. The 52-week high of the shares is $23.55 while the 52-week low is $6.43. According to the latest information available, the market cap of the company is $141 M.
Several Insider Transactions has been reported to the SEC. On Jul 19, 2016, Stephen R Brady (EVP, Strategy & Finance) purchased 1,500 shares at $6.84 per share price.Also, On Nov 24, 2015, Wayne Gombotz (Chief Development Officer) sold 5,000 shares at $20.00 per share price.On Aug 26, 2015, Lewis W Coleman (director) purchased 3,000 shares at $14.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms ZVex and GLAAS which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action. The Company’s primary product candidates CMB305 and G100 utilize multiple immuno-oncology approaches and it believes address the shortcomings of existing therapies. The Company’s immuno-oncology product candidates are being developed in two separate approaches. The Specific Antigen approach uses selected antigens that are also present in the patient’s tumor. The Endogenous Antigen approach relies on endogenous tumor antigens released during tumor lysis by treatments such as chemotherapy or local radiation.